Novel Androgen Deprivation Treatment for Advanced Prostate Cancer

Prostate cancer is the most common cancer diagnosed among men in the United States. Considered curable if diagnosed at a localized stage, the survival rate of men with metastatic disease is dramatically reduced. Due to the androgen-dependence of prostate cancer, androgen deprivation therapy (ADT) has been the mainstay and primary therapeutic approach for management of men with metastatic prostate cancer. Join Drs. Robert Dreicer and Michael Cookson as they review the principles of androgen deprivation therapy and discuss the latest clinical data for recently approved ADT agents and studies of